Overview Financials News + Filings IR Vault Key Docs Charts Holdings Ownership Insiders
|
|
SCICLONE PHARMACEUTICALS INC (SCLN)
|
Add to portfolio |
|
|
|
| Price: |
$11.15
| | Metrics |
| OS: |
51.7
|
M
| |
17
|
% ROE
|
| Market cap: |
$577
|
M
| |
60
|
% ROIC
|
|
Net cash:
|
$157
|
M
| |
$3.04
|
per share
|
|
EV:
|
$419
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$45.4
|
M
| |
9.2
|
x EV/EBITDA
|
|
EBIT
|
$44.4
|
M
| |
9.4
|
x EV/EBIT
|
| EPS |
$0.82
| |
13.6
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 160.1 | 157.3 | 134.8 | 127.1 | 156.3 | 132.6 | 85.1 | 72.4 |
| Revenue growth | 1.8% | 16.7% | 6.1% | -18.7% | 17.9% | 55.8% | 17.5% | 33.8% |
| Cost of goods sold | 22.9 | 22.3 | 23.0 | 17.7 | 149.9 | 19.4 | 62.7 | 59.8 |
| Gross profit | 137.2 | 134.9 | 111.8 | 109.4 | 6.4 | 113.2 | 22.4 | 12.6 |
| Gross margin | 85.7% | 85.8% | 82.9% | 86.1% | 4.1% | 85.4% | 26.3% | 17.4% |
| Sales and marketing | 54.7 | 54.0 | 48.5 | 55.2 | 70.3 | 48.9 | 22.0 | 18.8 |
| Research and development | 15.1 | 12.3 | 14.6 | 8.0 | 5.1 | | | |
| General and administrative | 34.2 | 27.9 | 22.7 | 32.5 | 21.3 | 24.0 | 15.6 | 12.5 |
| EBITA | 33.2 | 29.9 | 26.0 | 11.6 | 37.5 | 28.0 | 22.4 | 12.6 |
| EBITA margin | 20.8% | 19.0% | 19.3% | 9.1% | 24.0% | 21.1% | 26.3% | 17.4% |
| Amortization of intangibles | | | | | 2.6 | 2.5 | | |
| EBIT | 33.2 | 29.9 | 26.0 | 11.6 | 34.8 | 25.5 | 22.4 | 12.6 |
| EBIT margin | 20.8% | 19.0% | 19.3% | 9.1% | 22.3% | 19.2% | 26.3% | 17.4% |
| Pre-tax income | 34.1 | 30.3 | 26.4 | 13.2 | 6.3 | 28.8 | 23.3 | 12.6 |
| Income taxes | 3.4 | 0.8 | 1.2 | 2.2 | -3.3 | 0.7 | 2.2 | 0.6 |
| Tax rate | 10.0% | 2.7% | 4.4% | 17.0% | | 2.3% | 9.4% | 5.1% |
| Net income | 30.7 | 29.5 | 25.2 | 11.0 | 9.6 | 28.1 | 21.1 | 11.9 |
| Net margin | 19.2% | 18.7% | 18.7% | 8.6% | 6.2% | 21.2% | 24.8% | 16.5% |
| |
| Diluted EPS | $0.58 | $0.56 | $0.48 | $0.20 | $0.16 | $0.49 | $0.43 | $0.25 |
| Shares outstanding (diluted) | 52.6 | 52.2 | 52.7 | 54.9 | 58.5 | 57.4 | 49.4 | 47.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|